149 related articles for article (PubMed ID: 33886813)
21. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway.
Au Yeung CL; Tsang TY; Yau PL; Kwok TT
Oncogene; 2011 May; 30(21):2401-10. PubMed ID: 21242962
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration.
Roztocil E; Nicholl SM; Davies MG
J Surg Res; 2007 Jul; 141(1):83-90. PubMed ID: 17574041
[TBL] [Abstract][Full Text] [Related]
23. Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway.
Chou RH; Hsieh SC; Yu YL; Huang MH; Huang YC; Hsieh YH
PLoS One; 2013; 8(8):e71983. PubMed ID: 23940799
[TBL] [Abstract][Full Text] [Related]
24. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
[TBL] [Abstract][Full Text] [Related]
25. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract][Full Text] [Related]
26. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
27. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells.
Chandrasekar N; Mohanam S; Gujrati M; Olivero WC; Dinh DH; Rao JS
Oncogene; 2003 Jan; 22(3):392-400. PubMed ID: 12545160
[TBL] [Abstract][Full Text] [Related]
29. Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.
Rysenkova KD; Klimovich PS; Shmakova AA; Karagyaur MN; Ivanova KA; Aleksandrushkina NA; Tkachuk VA; Rubina KA; Semina EV
Cell Signal; 2020 Nov; 75():109741. PubMed ID: 32822758
[TBL] [Abstract][Full Text] [Related]
30. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
31. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration.
Mazzieri R; D'Alessio S; Kenmoe RK; Ossowski L; Blasi F
Mol Biol Cell; 2006 Jan; 17(1):367-78. PubMed ID: 16267271
[TBL] [Abstract][Full Text] [Related]
32. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
33. Protease-mediated human smooth muscle cell proliferation by urokinase requires epidermal growth factor receptor transactivation by triple membrane signaling.
Duru EA; Fu Y; Davies MG
J Surg Res; 2014 Dec; 192(2):254-62. PubMed ID: 25082749
[TBL] [Abstract][Full Text] [Related]
34. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
[TBL] [Abstract][Full Text] [Related]
35. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
36. Suppression of urokinase expression and invasion by a soybean Kunitz trypsin inhibitor are mediated through inhibition of Src-dependent signaling pathways.
Inagaki K; Kobayashi H; Yoshida R; Kanada Y; Fukuda Y; Yagyu T; Kondo T; Kurita N; Kitanaka T; Yamada Y; Sakamoto Y; Suzuki M; Kanayama N; Terao T
J Biol Chem; 2005 Sep; 280(36):31428-37. PubMed ID: 16002410
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway.
Shi X; Ran L; Liu Y; Zhong SH; Zhou PP; Liao MX; Fang W
Oncol Rep; 2018 Mar; 39(3):939-950. PubMed ID: 29328485
[TBL] [Abstract][Full Text] [Related]
38. Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathway.
Humtsoe JO; Kramer RH
Oncogene; 2010 Feb; 29(8):1214-26. PubMed ID: 19935697
[TBL] [Abstract][Full Text] [Related]
39. Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro.
Wang X; Jiang Z; An J; Mao X; Lin F; Sun P
Mol Med Rep; 2018 Mar; 17(3):4273-4280. PubMed ID: 29328476
[TBL] [Abstract][Full Text] [Related]
40. Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells.
Meira DD; de Almeida VH; Mororó JS; Nóbrega I; Bardella L; Silva RL; Albano RM; Ferreira CG
Br J Cancer; 2009 Sep; 101(5):782-91. PubMed ID: 19654571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
